Brief: Allarity Therapeutics Announces That The Stenoparib Drp® Test Has Received A Notice Of Allowance From The Us Patent And Trademark Office
27/04/2026 13:23
April 27 (Reuters) - Allarity Therapeutics Inc ALLR.O: ALLARITY THERAPEUTICS ANNOUNCES THAT THE STENOPARIB DRP® TEST HAS RECEIVED A NOTICE OF ALLOWANCE FROM THE US PATENT AND TRADEMARK OFFICE ALLARITY THERAPEUTICS INC - PATENT EXPECTED TO BE FORMALLY GRANTED WITHIN THREE MONTHS, SUBJECT TO STANDARD ADMINISTRATIVE PROCEDURES ALLARITY THERAPEUTICS INC - PATENT TO PROVIDE EXCLUSIVITY FOR STENOPARIB WITH DRP TEST INTO 2039 Source text: ID:nGNXfD2fQ Further company coverage: ALLR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allarity Therapeutics
See all newsBrief: Allarity Therapeutics Announces Strategic Capital Allocation For Filing Of Spac Registration Statement
Allarity Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Allarity Therapeutics Q2 loss narrows as expenses fall
Allarity Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Allarity Therapeutics Announces The Grant Of Essential U.S. Patent For Its Stenoparib Drp® Companion Diagnostic